Kidney Int 74:14341443 Flyvbjerg A, Frystyk J, Thorlacius-Ussing O, Orskov H (1989) Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats
Zibotentan is an antagonist targeting the ETA receptor and is currently undergoing Phase 2 clinical development for the treatment of portal hypertension, cirrhosis, albuminuria, type 2 diabetes, chronic kidney disease, liver disease, and more
For diabetes control: Some women develop gestational diabetes or have type 2 diabetes that needs ongoing management after birth
Rapid weight loss at any dose increases bile concentration and gallstone risk
Kim Kardashian long flowing hair, a little lighter color than she usually wears it
10.1523/JNEUROSCI.3579-15.2016 J